NASDAQ:INZY - Inozyme Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $36.00
  • Forecasted Upside: 93.55 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$18.60
▼ -0.18 (-0.96%)
1 month | 3 months | 12 months
Get New Inozyme Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INZY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INZY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$36.00
▲ +93.55% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Inozyme Pharma in the last 3 months. The average price target is $36.00, with a high forecast of $40.00 and a low forecast of $33.00. The average price target represents a 93.55% upside from the last price of $18.60.
Buy
The current consensus among 4 polled investment analysts is to buy stock in Inozyme Pharma.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/18/2020WedbushInitiated CoverageOutperform ➝ Outperform$35.00 ➝ $35.00Medium
i
Rating by D. Nierengarten at Wedbush
8/18/2020Bank of AmericaInitiated CoverageBuy$33.00Medium
i
8/18/2020Piper SandlerInitiated CoverageOverweight$40.00Medium
i
8/18/2020CowenInitiated CoverageOutperformMedium
i
(Data available from 4/22/2016 forward)
Inozyme Pharma logo
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $18.60
$18.60
$19.30

50 Day Range

MA: $19.84
$17.77
$22.14

52 Week Range

Now: $18.60
$16.10
$31.65

Volume

304 shs

Average Volume

59,217 shs

Market Capitalization

$436.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Inozyme Pharma?

The following Wall Street analysts have issued research reports on Inozyme Pharma in the last year: Bank of America Co., Cowen Inc, Piper Sandler, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for INZY.

What is the current price target for Inozyme Pharma?

3 Wall Street analysts have set twelve-month price targets for Inozyme Pharma in the last year. Their average twelve-month price target is $36.00, suggesting a possible upside of 93.5%. Piper Sandler has the highest price target set, predicting INZY will reach $40.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $33.00 for Inozyme Pharma in the next year.
View the latest price targets for INZY.

What is the current consensus analyst rating for Inozyme Pharma?

Inozyme Pharma currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INZY will outperform the market and that investors should add to their positions of Inozyme Pharma.
View the latest ratings for INZY.

What other companies compete with Inozyme Pharma?

How do I contact Inozyme Pharma's investor relations team?

The company's listed phone number is 857-330-4340 and its investor relations email address is [email protected] The official website for Inozyme Pharma is www.inozyme.com.